中美合资清远华能制药有限公司(简称“中美华能制药”)成立于1992年,原由清远市医药总公司和美国AMKO生技股份有限公司以4:6投资建成,今年因迁厂扩股增加两股东,现合资四方分别是清远市医药公司,占20%股份;清远通业股份有限公司,占20%股份;美国AMKO BIOTECH CO.,INC,占40%股份;英国 The Sino-U.S. joint venture Qingyuan Huaneng Pharmaceutical Co., Ltd. (abbreviated as “China U.S. Huaneng Pharmaceutical”) was established in 1992. It was originally built by Qingyuan Pharmaceutical Corporation and AMKO Biotech Co., Ltd. with an investment of 4:6. Two new shareholders were added to the stock, and the four joint ventures are now Qingyuan Pharmaceutical Co., Ltd., which holds 20% of the shares; Qingyuan Tongye Co., Ltd., which occupies 20% of the shares; American AMKO BIOTECH CO., INC, which holds 40% of the shares;